REG - Sareum Holdings PLC - Issue of Warrants

Sareum HoldingsAnnouncement

28/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220128:nRSb9092Za&default-theme=true

RNS Number : 9092Z  Sareum Holdings PLC  28 January 2022

Sareum Holdings plc

("Sareum" or the "Company")

Issue of Warrants

Cambridge, UK, 28 January 2022 - Sareum Holdings plc (AIM: SAR), the
specialist drug development company, announces that it has issued warrants
over 29,000,000 new ordinary shares of 0.025p each in the capital of the
Company to individuals who provided introductory services leading to the share
subscriptions announced by the Company during 2021. The warrants have an
exercise price of 5p per share, with exercise being conditional on the shares
having traded at or above 7p for five consecutive days, and a subscription
period that ends on 31 May 2022.

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                    01223 497700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                          020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel                                          020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                         020 3764 2341

 MEDiSTRAVA Consulting (Financial PR)

 Mark Swallow / George Underwood / Evelyn McCormack   0203 928 6900

About Sareum

Sareum is a specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases. The Company aims to generate value through licensing its candidates
to international pharmaceutical and biotechnology companies at the preclinical
or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine
kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical
development as therapies for autoimmune diseases, including the 'cytokine
storm' immune system overreaction to Covid-19 and other viral infections,
(SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral,
selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell
replication and DNA damage repair mechanisms. Preliminary Phase 2 and
comprehensive preclinical data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in genetically
defined patients.

SRA737 was discovered and initially developed by scientists at The Institute
of Cancer Research in collaboration with Sareum, and with funding from Sareum
and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to
Sierra Oncology Inc. Sierra continues to explore options that would enable the
development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

- Ends -

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIGDBUBDDGDR